LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Articles
Nikang Therapeutics Inc.
Headquarters:
Wilmington, DE, United States
Website:
http://www.nikangtx.com/
Year Founded:
2017
Status:
Private
BioCentury
|
Apr 18, 2024
Product Development
CDK2 inhibitors at AACR: An answer to CDK4/6 resistance?
AACR abstracts highlight CDK2 inhibition as solution to CDK4/6 resistance and route to reaching more cancer types
Read More
BioCentury
|
Jan 5, 2024
Management Tracks
Friedman succeeding Hoos at Scorpion
Plus: 4DMT hires Noriyuki Kasahara as CSO, and updates from SV, Omega, AbbVie Ventures, Nikang, Immunome, Wugen, Zevra and Quris
Read More
BioCentury
|
Jun 11, 2021
Management Tracks
Slavitt steps down from Biden’s pandemic response team; plus Ocugen, Flexion, Syros, Monte Rosa and more
Andy Slavitt has stepped down as senior adviser to the Biden administration’s coronavirus pandemic response team; the special government employee position limits service time to 130 days.
Read More
BioCentury
|
May 26, 2021
Finance
Building on discovery platform and early deals, CBC-backed NiKang adds $200M in crossover series C round
With backing from high-profile crossover investors, four-year-old company taking wholly-owned HIF2A program into clinic
Read More
BioCentury
|
Apr 24, 2020
Product Development
April 23 Quick Takes: Hansoh, NiKang partner for antiviral; plus Jakafi, Avastin, EpimAb-QIMR, ProThera-Takeda
Jakafi meets in Phase III for GvHD; low dose Avastin for retinopathy of prematurity
Read More
BioCentury
|
Nov 5, 2019
Company News
Nov. 4 Company Quick Takes: FDA approves RedHill’s antibiotic; plus NiKang, Revolution-Amgen, Aveo and Tmunity-Oncora
Read More
Items per page:
10
1 - 6 of 6
Username
Elevio by Dixa